The abnormal aggregation of β-amyloid (Aβ) peptides in the brain is a major pathological
hallmark of Alzheimer's disease (AD). The suppression (or alteration) of Aβ aggregation is …

Abnormal aggregation of β-amyloid (Aβ) peptides is a major hallmark of Alzheimer's disease
(AD). In spite of numerous attempts to prevent the β-amyloidosis, no effective drugs for …

The intracellular Tau aggregates are known to be associated with Alzheimer's disease. The
inhibition of Tau aggregation is an important strategy for screening of therapeutic molecules …

The abnormal aggregation of β-amyloid (Aβ) peptides is a hallmark of Alzheimer's disease
(AD) that affects more than 10% of the people over the age 60 world-wide. While the exact …

The self-assembly of β-amyloid (Aβ) peptides into highly stable plaques is a major hallmark
of Alzheimer's disease. Here, we report visible light-driven dissociation of β-sheet-rich Aβ …

The abnormal self-assembly of amyloid-β protein (Aβ) into toxic aggregates is a major
pathological hallmark of Alzheimer's disease (AD). Modulation of Aβ fibrillization with …

Amyloid-β (Aβ) peptide as one of the main components of senile plaques is closely related
to the onset and progression of incurable Alzheimer's disease (AD). Numerous efforts have …

The formation of amyloid-β (Aβ) plaques in the brain is one of the main pathological features
of Alzheimer's disease (AD). The imaging probes, capable of detecting A β deposition, are …

The self-assembly of the beta-amyloid peptide (Aβ) into amyloid aggregates is a central
phenomenon associated with Alzheimer's disease. Here, we report chemical modifications …

Aggregation of amyloid β-peptide (Aβ) is closely related to the pathology of Alzheimer's
disease (AD). In this pathology, the beginning stage is characterized by excessive …